Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
renal cell cancer (RCC), VEGF(R) inhibitor vs. nivolumab plus ipilimumab, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 214 (all population), 2017 0.68 [0.49; 0.95]
CheckMate 214 (favorable risk) EXPLORATORY, 2017 1.45 [0.51; 4.12]
CheckMate 214 (intermediate and poor risk), 2017 0.63 [0.44; 0.90]
0.69 [0.53 ; 0.88 ] CheckMate 214 (all population), 2017, CheckMate 214 (favorable risk) EXPLORATORY, 2017, CheckMate 214 (intermediate and poor risk), 2017 3 9% 2,192 moderate not evaluable deaths (OS) (extension)detailed results CheckMate 214 (all population), 2017 0.71 [0.59; 0.86]
CheckMate 214 (favorable risk) EXPLORATORY, 2017 1.22 [0.73; 2.04]
CheckMate 214 (intermediate and poor risk), 2017 0.66 [0.54; 0.80]
0.75 [0.59 ; 0.94 ] CheckMate 214 (all population), 2017, CheckMate 214 (favorable risk) EXPLORATORY, 2017, CheckMate 214 (intermediate and poor risk), 2017 3 58% 2,192 moderate not evaluable PFS (extension)detailed results CheckMate 214 (all population), 2017 0.85 [0.73; 0.98]
CheckMate 214 (favorable risk) EXPLORATORY, 2017 1.23 [0.90; 1.69]
CheckMate 214 (intermediate and poor risk), 2017 0.77 [0.65; 0.91]
0.89 [0.73 ; 1.09 ] CheckMate 214 (all population), 2017, CheckMate 214 (favorable risk) EXPLORATORY, 2017, CheckMate 214 (intermediate and poor risk), 2017 3 70% 1,345 moderate not evaluable progression or deaths (PFS)detailed results CheckMate 214 (all population), 2017 0.98 [0.79; 1.22]
CheckMate 214 (favorable risk) EXPLORATORY, 2017 2.18 [1.29; 3.68]
CheckMate 214 (intermediate and poor risk), 2017 0.82 [0.64; 1.05]
1.12 [0.75 ; 1.68 ] CheckMate 214 (all population), 2017, CheckMate 214 (favorable risk) EXPLORATORY, 2017, CheckMate 214 (intermediate and poor risk), 2017 3 82% 1,958 moderate not evaluable objective responses (ORR)detailed results CheckMate 214 (all population), 2017 1.35 [1.05; 1.73]
CheckMate 214 (favorable risk) EXPLORATORY, 2017 0.64 [0.39; 1.07]
CheckMate 214 (intermediate and poor risk), 2017 1.98 [1.48; 2.64]
1.25 [0.75 ; 2.09 ] CheckMate 214 (all population), 2017, CheckMate 214 (favorable risk) EXPLORATORY, 2017, CheckMate 214 (intermediate and poor risk), 2017 3 86% 2,192 moderate not evaluable objective responses (ORR) (extension)detailed results CheckMate 214 (all population), 2017 1.36 [1.06; 1.74]
CheckMate 214 (favorable risk) EXPLORATORY, 2017 0.64 [0.39; 1.07]
CheckMate 214 (intermediate and poor risk), 2017 1.70 [1.28; 2.26]
1.20 [0.78 ; 1.86 ] CheckMate 214 (all population), 2017, CheckMate 214 (favorable risk) EXPLORATORY, 2017, CheckMate 214 (intermediate and poor risk), 2017 3 81% 2,192 moderate not evaluable TRAE (any grade)detailed results CheckMate 214 (all population), 2017 0.41 [0.22; 0.76]
0.41 [0.22 ; 0.76 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.49 [0.39; 0.63]
0.49 [0.39 ; 0.63 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable TRAE leading to death (grade 5)detailed results CheckMate 214 (all population), 2017 1.97 [0.59; 6.58]
1.97 [0.59 ; 6.58 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable TRAE leading to discontinuation (any grade)detailed results CheckMate 214 (all population), 2017 1.98 [1.42; 2.74]
1.98 [1.42 ; 2.74 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Acute kidney injury TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 1.31 [0.29; 5.86]
1.31 [0.29 ; 5.86 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 21.94 [1.29; 374.25]
21.94 [1.29 ; 374.25 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Anaemia TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.08 [0.02; 0.35]
0.08 [0.02 ; 0.35 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.75 [0.33; 1.72]
0.75 [0.33 ; 1.72 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Blister TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.16 [0.01; 3.25]
0.16 [0.01 ; 3.25 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Blood creatinine increased TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.49 [0.04; 5.40]
0.49 [0.04 ; 5.40 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Colitis TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 21.94 [1.29; 374.25]
21.94 [1.29 ; 374.25 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 1.14 [0.38; 3.42]
1.14 [0.38 ; 3.42 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Diabetes TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 11.86 [0.66; 212.80]
11.86 [0.66 ; 212.80 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Diarrhoea TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.65 [0.37; 1.14]
0.65 [0.37 ; 1.14 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Dysgeusia TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.49 [0.02; 14.59]
0.49 [0.02 ; 14.59 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Dyspepsia TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.98 [0.02; 49.38]
0.98 [0.02 ; 49.38 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Eczema TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.98 [0.02; 49.38]
0.98 [0.02 ; 49.38 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Endocrine disorders TRAE (grade 3-4) detailed results CheckMate 214 (all population), 2017 39.87 [5.45; 291.45]
39.87 [5.45 ; 291.45 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Erythema TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.98 [0.02; 49.38]
0.98 [0.02 ; 49.38 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.44 [0.26; 0.72]
0.44 [0.26 ; 0.72 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results CheckMate 214 (all population), 2017 0.84 [0.50; 1.43]
0.84 [0.50 ; 1.43 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 214 (all population), 2017 2.42 [1.41; 4.14]
2.42 [1.41 ; 4.14 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Hypertension TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.04 [0.01; 0.10]
0.04 [0.01 ; 0.10 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 3.92 [0.18; 87.20]
3.92 [0.18 ; 87.20 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Hypophysitis TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 30.14 [1.80; 505.79]
30.14 [1.80 ; 505.79 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Hypothyroidism TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 1.96 [0.18; 21.68]
1.96 [0.18 ; 21.68 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Increase AST TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 2.86 [1.20; 6.83]
2.86 [1.20 ; 6.83 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Increased ALT TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 3.15 [1.47; 6.75]
3.15 [1.47 ; 6.75 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Increased lipase level TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 1.61 [1.04; 2.49]
1.61 [1.04 ; 2.49 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 7.93 [0.99; 63.59]
7.93 [0.99 ; 63.59 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Mucosal inflammation TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.06 [0.01; 0.48]
0.06 [0.01 ; 0.48 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 1.12 [0.40; 3.11]
1.12 [0.40 ; 3.11 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Palmar-plantar erythrodysaesthesia syndrome TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.02 [0.00; 0.13]
0.02 [0.00 ; 0.13 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 1.96 [0.07; 58.49]
1.96 [0.07 ; 58.49 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Pruritus generalised TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.98 [0.02; 49.38]
0.98 [0.02 ; 49.38 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Pruritus TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 5.90 [0.29; 117.97]
5.90 [0.29 ; 117.97 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Rash TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 17.88 [1.03; 309.26]
17.88 [1.03 ; 309.26 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 214 (all population), 2017 1.14 [0.38; 3.42]
1.14 [0.38 ; 3.42 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results CheckMate 214 (all population), 2017 11.86 [0.66; 212.80]
11.86 [0.66 ; 212.80 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results CheckMate 214 (all population), 2017 0.36 [0.21; 0.60]
0.36 [0.21 ; 0.60 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Skin exfoliation TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.98 [0.02; 49.38]
0.98 [0.02 ; 49.38 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Skin hypopigmentation TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.98 [0.02; 49.38]
0.98 [0.02 ; 49.38 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Stomatitis TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.03 [0.00; 0.57]
0.03 [0.00 ; 0.57 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Thrombocytopenia TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.02 [0.00; 0.34]
0.02 [0.00 ; 0.34 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Thyroiditis TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 1.96 [0.07; 58.49]
1.96 [0.07 ; 58.49 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Urticaria TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 1.96 [0.07; 58.49]
1.96 [0.07 ; 58.49 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable Vomiting TRAE (grade 3-4)detailed results CheckMate 214 (all population), 2017 0.39 [0.12; 1.24]
0.39 [0.12 ; 1.24 ] CheckMate 214 (all population), 2017 1 0% 1,082 NA not evaluable 0.0 100.0 1.0 relative treatment effect www.metaEvidence.org 2024-09-28 03:44 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 10,93,79,178,152,80
- treatments: 776,1069,693,1068,900,1084,1016,1323,985,604,1014,1447,1476,1477,777,1027,1028,669,1564,670,1015,1023,506,908